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PCLINICAL RESEARCH Cardiometabolic Risk
Lipoprotein(a), Hormone Replacement Therapy,
and Risk of Future Cardiovascular Events
Jacqueline Suk Danik, MD, MPH,*†‡ Nader Rifai, PHD, Julie E. Buring, SCD,†‡
Paul M Ridker, MD, MPH*†‡§
Boston, Massachusetts
Objectives This study assesses whether the relationship of lipoprotein(a) [Lp(a)] with cardiovascular risk may be modified
by concurrent hormone replacement therapy (HT).
Background Prior studies indicate that HT decreases plasma levels of Lp(a), but few have been powered to assess whether it
modifies the relationship of Lp(a) with cardiovascular disease (CVD).
Methods Lipoprotein(a) at baseline was measured among 27,736 initially healthy women, of whom 12,075 indicated ac-
tive HT use at the time of blood draw at study initiation and 15,661 did not. The risk of first-ever major cardio-
vascular event (nonfatal myocardial infarction, nonfatal cerebrovascular event, coronary revascularization, or
cardiovascular death) over a 10-year period was assessed with Cox proportional hazard models according to
Lp(a) levels and HT status and adjusted for potential confounding variables.
Results As anticipated, Lp(a) values were lower among women taking HT (median 9.4 mg/dl vs. 11.6 mg/dl, p 
0.0001). In women not taking HT, the hazard ratio of future CVD for the highest Lp(a) quintile compared with the
lowest was 1.8 (p trend 0.0001), after adjusting for age, smoking, blood pressure, diabetes, body mass index,
total cholesterol, high-density lipoprotein, C-reactive protein, and treatment arms of aspirin and vitamin E. In
contrast, among women taking HT, there was little evidence of association with CVD (hazard ratio: 1.1, p trend
 0.18; interaction p value  0.0009 between Lp(a) quintiles and HT on incident CVD).
Conclusions The relationship of high Lp(a) levels with increased CVD is modified by HT. These data suggest that the predic-
tive utility of Lp(a) is markedly attenuated among women taking HT and may inform clinicians’ interpretation of
Lp(a) values in such patients. (Women’s Health Study [WHS]; NCT00000479) (J Am Coll Cardiol 2008;52:
124–31) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.009m
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tipoprotein(a) [Lp(a)] is a lipoprotein that differs from
ow-density lipoprotein cholesterol (LDL-C) by the pres-
nce of an apolipoprotein(a) [apo(a)] component that has
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July 8, 2008:124–31 Lp(a), Hormone Therapy, and Risk of CVDhey also have high LDL-C levels (7), in concordance with
ork by other groups (8–14). However, data about what
odifies the relationship of Lp(a) with CVD are scarce. In
erms of lifestyle, changes in diet and exercise are not known
o decrease Lp(a) levels (15). In terms of medications, statin
herapy may not decrease Lp(a) levels, but by lowering
DL-C, may modify the cardiovascular risk associated with
p(a) (16); niacin, although difficult to tolerate in doses
eeded to decrease Lp(a) (17–19), does decrease Lp(a)
evels. The data about the relationship between hormone
eplacement therapy (HT) and Lp(a) levels are conflicting
nd controversial, in part because HT use in women is itself
ontroversial (20–25) and because studies that show de-
reases in Lp(a) levels with HT use (26–31) have rarely
een powered to assess for impact on CVD (32).
To explore this issue in detail, we undertook a study in
hich we assessed whether the relationship of Lp(a) levels
ith CVD is modified by concurrent use of HT among
7,736 women.
ethods
tudy population. Lipoprotein(a) was measured among
2,075 women taking HT and 15,661 not taking HT at the
nitiation of the study, and assessed for future cardiovascular
vents. Study participants were enrolled in the WHS
Women’s Health Study), a recently completed random-
zed, double-blinded, placebo-controlled clinical trial of
ow-dose aspirin and vitamin E, in the primary prevention
f CVD and cancer in U.S. female health care professionals
33–35). Eligible participants were apparently healthy
omen, age 45 years or older, who were free of self-reported
VD or cancer at study entry (1992 to 1998) with follow-up
or incident CVD through February 2005. At the time of
nrollment between 1992 and 1995, participants provided
nformation on whether they were currently taking HT and
rovided blood samples from which Lp(a) levels were
ssayed. They also provided demographic, medical history,
edication, and lifestyle data, as well as consent for blood-
ased analyses related to the risk of incident chronic
iseases. In total, 27,736 women who provided blood
amples for successful Lp(a) analysis, and who also re-
ponded to questions about HT, constituted the study
opulation for this analysis.
The study was approved by the institutional review board of
he Brigham and Women’s Hospital (Boston, Massachusetts).
aseline plasma measurements. Among WHS partici-
ants, 27,736 provided data about HT at baseline and also
rovided baseline blood samples that were stored in liquid
itrogen (150°C to 180°C) until the time of analysis.
hese samples underwent Lp(a) and lipid analysis in a core
aboratory certified by the National Heart, Lung, and Blood
nstitute/Centers for Disease Control and Prevention Lipid
tandardization Program. Because of poor agreement of
p(a) values obtained by different methods (5), we used the
nly commercially available assay shown by the National (eart, Lung, and Blood Institute
nd International Federation of
linical Chemistry Lp(a) stan-
ardization groups to not be af-
ected by Kringle IV-Type 2 re-
eats (5). We determined the
oncentration of Lp(a) using a
urbidimetric assay on the Hita-
hi 917 analyzer (Roche Diag-
ostics, Indianapolis, Indiana),
sing reagents and calibrators
rom Denka Seiken (Niigata, Ja-
an). The interassay coefficient
f variation of Lp(a) concen-
rations of 17.6 and 58.1 mg/dl
ere 3.6% and 1.5%, respectively.
High-sensitivity C-reactive protein (CRP) was measured
sing a validated immunoturbidometric method (Denka
eiken, Tokyo, Japan) (36). Total cholesterol was measured
nzymatically. High-density lipoprotein (Roche Diagnos-
ics, Basel, Switzerland) and LDL-C (Genzyme Corpora-
ion, Cambridge, Massachusetts) were measured by a ho-
ogenous direct method. All lipid determinations were
erformed on the Hitachi 917 analyzer; 98% of the
amples received underwent successful evaluation for each
iomarker.
scertainment of incident cardiovascular events. All
articipants were followed prospectively for the occurrence
f the composite end point of first ever major cardiovascular
vent (nonfatal myocardial infarction, nonfatal ischemic
troke, coronary revascularization, or cardiovascular death).
edical records were obtained and reviewed for confirma-
ion of events by 2 cardiologists. Deaths of cardiovascular
auses were confirmed by autopsy reports, death certificates,
edical records, and contact with family members.
tatistical analysis. Baseline characteristics such as age,
ody mass index, smoking status, presence of diabetes,
ypertension, family history of premature myocardial in-
arction, lipid profiles, CRP levels, and post-menopausal
tatus in women on HT, and measures of socioeconomic
tatus such as income and education, were compared with
hose of women free of HT.
Next, Lp(a) was divided into quintiles on the basis of
heir distribution in the entire WHS cohort, and these
uintile cut points were then used to assess for evidence of
nteraction between overall Lp(a) quintiles and HT status in
ox proportional hazard models that regressed CVD on
p(a) quintiles, HT status, and an interaction term of Lp(a)
uintiles multiplied by HT status.
Because of evidence of interaction from this evaluation,
e recalculated Lp(a) quintile cutoffs separately within each
T strata and then applied these cutoffs to subsequent
nalysis separately within HT strata. Hazard ratios (HRs),
omparing Lp(a) quintiles 2 through 5 with the lowest
Abbreviations
and Acronyms
apo(a)  apolipoprotein(a)
CRP  C-reactive protein
CVD  cardiovascular
disease
HR  hazard ratio
HT  hormone replacement
therapy
LDL  low-density
lipoprotein
LDL-C  low-density
lipoprotein cholesterol
Lp(a)  lipoprotein(a)referent) quintile, were calculated by Cox proportional
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Lp(a), Hormone Therapy, and Risk of CVD July 8, 2008:124–31azard models, in models that adjusted first for age (years),
hen for Framingham covariates as suggested by the most
ecent National Cholesterol Education Program Adult
reatment Panel III guidelines (37,38), and finally in fully
djusted models that adjusted for age, blood pressure (as
efined by Framingham risk models [120/75 mm Hg,
20 to 129/75 to 84 mm Hg, 130 to 139/85 to 89 mm Hg,
40 to 159/90 to 94 mm Hg, and 160/95 mm Hg],
iabetes, current smoking status, body mass index (linear
ontinuous), total cholesterol, high-density lipoprotein,
RP, and treatment arms. These variables were chosen a
riori for their impact on CVD. Tests for trend across
uintiles of Lp(a) were addressed by entering a single
Baseline Characteristics Among WomenAccording to A ive HT Status at Ti of Blood
Table 1 Baseline Characteristics Among WoAccording to Active HT Status at T
Age, yrs
Body mass index, kg/m2
Body mass index (WHO categories), kg/m2, %
25
25–29.9
30
Smoker, %
Never
Past
Current
Diabetes, %
History of hypertension, %
Family history of myocardial infarction in a parent before
age 60 yrs, %
Lp(a), mg/dl, median (IQR)
Total cholesterol, mg/dl
HDL
LDL
Triglyceride level (mg/dl), median (IQR)
C-reactive protein (mg/dl), median (IQR)
Income, %
19,999/yr
20,000–29,999/yr
30,000–39,999/yr
40,000–49,999/yr
50,000–99,999/yr
100,000/yr
Education, %
LPN, LVN
RN, 2 year
RN, 3 year
BS
Master, doctorate, MD
Caucasian, %
Values shown for continuous variables are mean SD unless otherwis
percentiles. Ranked tests of significance (the Wilcoxon rank sum tes
normally distributed, such as lipoprotein(a), triglycerides, and C-reactive
low-density lipoprotein were compared using a nonpaired t test. Diffe
BS bachelor degree; HDL high-density lipoprotein; HT hormon
licensed practical or vocational nurse; MD medical degree; RN, 2 year/RN,
Health Organization.rdinal term for each quintile based on the median value for
p(a) within each quintile.
After stratification by HT, Kaplan-Meier curves were
onstructed to illustrate cumulative event rates of CVD as a
unction of Lp(a) quintiles over an average of 10 years of
ollow up.
Because prior evidence has pointed to increased associa-
ions of Lp(a) with CVD in women with concomitant
levations of LDL-C, we assessed for joint associations of
p(a), LDL-C, and HT with CVD by calculating HRs for
VD by increasing quintiles of Lp(a) in: 1) women with
DL-C  median (121.4 mg/dl) who were taking HT; 2)
omen with LDL-C  median not taking HT; 3) women
f Blood Draw
ctive HT Users
(n  12,075)
No HT Use
(n  15,661) p Value
55.0 6.2 53.5 7.6 0.0001
25.4 4.5 26.3 5.3 0.0001
55.0 49.2
30.7 30.7
14.4 20.2 0.0001
50.9 52.3
38.3 35.5
10.8 12.2 0.0001
2.1 3.4 0.0001
25.7 24.6 0.03
12.7 13.0 0.54
9.4 (3.9–30.4) 11.6 (4.9–34.3) 0.0001
214.3 41.1 209.9 42.2 0.0001
57.3 15.6 51.0 14.0 0.0001
121.0 33.2 126.6 34.8 0.0001
2.0 (92.0–188.0) 111.0 (77.0–165.0) 0.0001
2.8 (1.3–5.4) 1.5 (0.6–3.5) 0.0001
3.8 6.2
8.7 10.5
13.6 14.2
17.0 16.3
43.0 40.3
14.0 12.5 0.0001
11.5 13.2
11.8 10.8
32.3 32.0
23.8 23.5
20.7 20.5 0.0001
95.9 94.9 0.0054
ted. Interquartile range (IQR) is the range between the 25th and 75th
used to assess for differences in continuous variables that were not
n. Age, bodymass index, total cholesterol, high-density lipoprotein and
in frequencies among groups were assessed by chi-square tests.
py; LDL low-density lipoprotein; Lp(a) lipoprotein(a); LPN, LVNDraw
men
ime o
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July 8, 2008:124–31 Lp(a), Hormone Therapy, and Risk of CVDith LDL-C  median taking HT; and 4) women with
DL-C  median not taking HT.
To test the strength of our findings, we performed
ensitivity analysis using alternative models. Alternative
odels included those that replaced total cholesterol with
DL, that replaced body mass index with waist circumfer-
nce, models analyzed within white subjects only, and then
odels that further adjusted for income (categories included
$19,999 per year, $20,000 to $29,900 per year, $30,000 to
39,900 per year, $40,000 to $49,900 per year, $50,000 to
99,900 per year, and $100,000 per year) and education
categories included licensed practical or vocational nurse
LPN, LVN], registered nurse with 2 or 3 years of training
RN 2 year, 3 year], bachelor degree [BS], master, doctor-
te, or medical degree [MD]). Finally, we divided women
aking HT into those taking estrogen only and those taking
strogen plus progesterone combinations, and performed
he Cox proportional hazard models for CVD to assess
hether the type of HT affected the relationship between
p(a) and CVD.
All p values are 2-tailed, with a value of0.05 considered
ignificant. Data analysis was conducted using SAS statis-
ical software version 9.1 (SAS Institute Inc., Cary, North
arolina) and SPLUS version 6.0 (Insightful Corp., Seattle,
ashington).
esults
omen taking HT at study initiation were older, had
igher total cholesterol, high-density lipoprotein, and CRP
evels, and were more likely to be hypertensive compared
ith women not on HT. They were also more likely to be
n higher income brackets and to report longer years of
ducation, but no relationships were seen between income
r education and Lp(a) levels. Women on HT also had
ower mean low-density lipoprotein (LDL) levels, and were
ess likely to be diabetic or to be current smokers (Table 1).
Overall assessment of the relationship between Lp(a),
T, and CVD revealed significant interaction between
ssociation of Lipoprotein(a) With Incident Cardiovascular Diseasen Women N t Taking Hormone Replacement Therapy
Table 2 Association of Lipoprotein(a) With Incident Cardiovascin Women Not Taking Hormone Replacement Therapy
Lipoprotein(a) 1 2
Median (Range), mg/dl* 2.10 (0.10–3.90) 6.00 (4.00–8.30) 11.
Women Not Taking Hormone R
Number of events 95 (3.0%) 86 (2.8%)
Person-yrs of follow-up 31,395 30,877
HR (95% CI)
Age adjusted 1 0.93 (0.70–1.25) 0
Framingham adjusted† 1 0.93 (0.69–1.24) 0
Fully adjusted‡ 1 0.97 (0.72–1.31) 0
Lipoprotein(a) quintile levels were derived from the stratum of women not taking hormone repla
ategories, current smoking status, total cholesterol, and high-density lipoprotein values. ‡Fully ad
otal cholesterol, and high-density lipoprotein values as well as body mass index, diabetes, C-reactive pro
CI  confidence interval; HR  hazard ratio.p(a) quintiles and HT status on CVD (p interaction 
.0009).
The different relationships of Lp(a) with CVD, therefore,
tratifying for HT therapy status, are shown in Tables 2 to
. In women free of HT (Table 2), women in the highest
uintile of Lp(a) (45.4 mg/dl in HT strata) were 1.77
imes more likely to develop cardiovascular events than
hose in the lowest quintile (3.9 mg/dl; p trend 0.0001)
n analyses adjusting for age, smoking, blood pressure, body
ass index, cholesterol, high-density lipoprotein, diabetes,
ormone use, CRP, and randomization treatment arms. A
hreshold effect is seen such that risk increased predomi-
antly among women with Lp(a) levels in the highest
uintile (66.35 mg/dl) and particularly in women with high
DL (Table 3), as noted previously (7).
In contrast, in women taking HT (Table 4), the relation-
hip of Lp(a) levels to CVD was attenuated, with loss of
ignificance of the relationship between the highest quintile
f Lp(a) (42.0 mg/dl in women taking HT, with HR of
.13, top vs. bottom quintile) and CVD (p trend  0.18 in
ully adjusted model), and even modified among women
ith elevated LDL, in whom synergistic elevations of CVD
isk are seen (Table 5).
In sensitivity analyses, further adjustment for income and
ducation, replacement of total cholesterol with LDL, and
hen replacement of body mass index with waist circumfer-
nce did not change the effect modification shown graphi-
ally in Figure 1, in which high levels of Lp(a) predict CVD
n women free of HT, but not in women on HT. The same
elationships are seen in analyses limited to Caucasian
ubjects only.
To address the potential for misclassification of exposure
uring follow-up, we repeated these analyses censoring
ollow-up time whenever a change in participant HT status
ccurred. In this censored analysis, the adjusted HR com-
aring the highest to lowest quintiles of Lp(a) on risk of all
VD was 1.96 (95% confidence interval [CI]: 1.40 to 2.76),
value if anything larger than that of the uncensored
Disease
Quintiles
3 4 5
40–16.70) 25.90 (16.80–45.30) 66.35 (45.40–239.60) p Trend
ement Therapy (n  15,661)
6%) 97 (3.1%) 166 (5.3%)
999 30,723 30,549
61–1.10) 0.95 (0.72–1.26) 1.67 (1.30–2.15) 0.0001
60–1.10) 0.90 (0.67–1.20) 1.64 (1.27–2.12) 0.0001
68–1.26) 0.97 (0.72–1.30) 1.77 (1.36–2.30) 0.0001
therapy. †Framingham-adjusted model refers to adjustments for covariates age, blood pressure
odels refer to Framingham covariates of age, blood pressure categories, current smoking status,ular
70 (8.
eplac
81 (2.
30,
.82 (0.
.82 (0.
.92 (0.
cement
justed mtein, and treatment arms.
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Lp(a), Hormone Therapy, and Risk of CVD July 8, 2008:124–31nalysis (HR: 1.77; 95% CI: 1.36 to 2.30). In contrast,
mong women taking HT, the relationship of Lp(a) levels
o CVD was attenuated, concordant with the uncensored
nalysis.
Last, assessing the relationship between Lp(a) and CVD
n women taking estrogen versus estrogen plus progestin
ormulas did not show any differences from the data for HT
s a whole (Online Appendixes 1 and 2).
iscussion
n this prospective study of 27,736 initially healthy women,
e found that Lp(a) is a determinant of risk of CVD among
omen free of HT, but that little such relationship is seen
mong HT users. This effect modification persists after
djustment for traditional cardiovascular risk factors and
ipoprotein(a), LDL-C, and Hazard Ratios of Future Cardiovascular Em ng Women Not Taking Hormone Replacement Therapy
Table 3 Lipoprotein(a), LDL-C, and Hazard Ratios of Future CarAmong Women Not Taking Hormone Replacement The
Lipoprotein(a) 1 2
Median (Range), mg/dl* 2.10 (0.10–3.90) 6.00 (4.00–8.30) 11.7
Women Not Taking Hormone Replacemen
Number of events 55 (3.8%) 50 (3.4%) 5
Person-yrs of follow-up 14,184 14,501
HR (95% CI)
Age adjusted 1 0.91 (0.62–1.34) 0.9
Framingham adjusted‡ 1 0.89 (0.61–1.31) 0.9
Fully adjusted§ 1 0.99 (0.67–1.48) 1.0
Women Not Taking Hormone Replacemen
Number of events 40 (2.3%) 36 (2.2%) 2
Person-yrs of follow-up 17,211 16,376
HR (95% CI)
Age adjusted 1 0.95 (0.60–1.49) 0.6
Framingham adjusted‡ 1 0.99 (0.63–1.56) 0.6
Fully adjusted§ 1 0.92 (0.58–1.47) 0.7
Lipoprotein(a) quintile levels were derived from women not taking hormone replacement ther
ovariates age, blood pressure categories, current smoking status, total cholesterol, and high-de
ategories, current smoking status, total cholesterol, and high-density lipoprotein values as well a
Abbreviations as in Tables 1 and 2.
ipoprotein(a) and Incident Cardiovascular Disease in Women Taki
Table 4 Lipoprotein(a) and Incident Cardiovascular Disease in
Lipoprotein(a) 1 2
Median (Range), mg/dl* 1.70 (0.10–3.00) 4.90 (3.10–6.80) 9.5
Women Taking Hormone Re
Number of events 86 (3.5%) 78 (3.3%)
Person-yrs of follow-up 24,593 23,620
HR (95% CI)
Age adjusted 1 0.96 (0.71–1.30) 0
Framingham adjusted† 1 1.02 (0.75–1.38) 0
Fully adjusted‡ 1 1.04 (0.76–1.42) 0
Lp(a) quintile levels were derived from the stratum of women taking hormone replacement ther
urrent smoking status, total cholesterol, and high-density lipoprotein values. ‡Fully adjusted m
holesterol, and high-density lipoprotein values as well as body mass index, diabetes, C-reactive protein,
Abbreviations as in Table 2.ocioeconomic variables such as income and education.
uantitatively, the HRs are 1.77 in HT-negative women
nd only 1.13 in HT-positive women when comparing the
op with the bottom Lp(a) quintiles in respective strata.
his effect modification is seen even among women with
oncomitant elevations of Lp(a) and LDL-C, who have the
ighest incidence of CVD.
We believe that there are at least 2 different explana-
ions for the effect modification seen. For one, it could be
ttributable to biological interaction between plasma
p(a) levels and concurrent HT use, which is why it was
mportant to measure HT status at the same time blood
as drawn. Alternatively, HT use may be a surrogate
ariable for healthy lifestyles, not fully captured by the
ovariates addressed here that ameliorate deleterious
s
scular Events
Quintiles
4 5
0–16.70) 25.90 (16.80–45.30) 66.35 (45.40–239.60) p Value
apy With LDL-C > Median† (n  8,269)
%) 67 (3.8%) 139 (6.9%)
66 17,370 19,540
4–1.35) 0.94 (0.66–1.35) 1.80 (1.32–2.46) 0.0001
2–1.31) 0.90 (0.62–1.29) 1.87 (1.36–2.56) 0.0001
1–1.53) 1.03 (0.71–1.50) 2.06 (1.49–2.86) 0.0001
apy With LDL-C < Median† (n  7,392)
%) 30 (2.2%) 27 (2.4%)
33 13,353 11,010
6–1.00) 0.91 (0.57–1.46) 1.07 (0.66–1.74) 0.45
0–1.13) 0.98 (0.60–1.58) 1.18 (0.72–1.93) 0.30
6–1.30) 0.89 (0.54–1.48) 1.25 (0.76–2.06) 0.23
edian LDL-C value was 121.4 mg/dl. ‡Framingham-adjusted model refers to adjustments for
oprotein values. §Fully adjusted models refer to Framingham covariates of age, blood pressure
mass index, diabetes, C-reactive protein, and treatment arms.
rmone Replacement Therapy
en Taking Hormone Replacement Therapy
Quintiles
3 4 5
0–13.60) 22.20 (13.70–41.90) 64.40 (42.00–221.90) p Value
ent Therapy (n  12,075)
4%) 58 (2.4%) 94 (3.9%)
537 23,877 23,864
49–0.96) 0.69 (0.50–0.97) 1.11 (0.83–1.49) 0.11
50–0.98) 0.72 (0.52–1.01) 1.07 (0.80–1.44) 0.27
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otential direct biological effects, it is intriguing that
ecent data show that: 1) estrogen may induce increased
ptake of Lp(a) by the LDL receptor (39,40); 2) it may
ause reduction of Lp(a) production by the liver (30),
here Lp(a) production is likely modulated (41– 43); and
) certain cholesterol metabolites may interact directly
ith HT in the vasculature (44).
Strengths of our study include the reliable measurement
f Lp(a), using a reproducible apo(a) isoform-independent
0 2 4 6 8 10 12
Years of Follow-Up
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
0.
06
P
ro
ba
bi
lit
y 
of
 C
ar
di
ov
as
cu
la
r 
E
ve
nt
Probability of Cardiovascular Events According to Increasing
Quintiles of Lp(a) Levels in Women Not Taking HRT
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
0.
06
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
0.
06
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
0.
06
0.
00
0.
01
0.
02
0.
03
0.
04
0.
05
0.
06
Quintile 5
Quintile 4
Quintile 3
Quintile 2
Quintile 1
Figure 1 Cumulative Incidence of Major Cardiovascular Disease
The probability of cardiovascular events according to increasing lipoprotein(a) [Lp(a
ment therapy (HT) (left) and among women taking HT at study initiation (right). Qu
separately within the 2 groups of women.
ipoprotein(a), LDL-C, and Hazard Ratios of Future Cardiovascular Em ng Women Taking Hormone Replacement Th rapy
Table 5 Lipoprotein(a), LDL-C, and Hazard Ratios of Future CarAmong Women Taking Hormone Replacement Therapy
Lipoprotein(a) 1 2
Median (Range), mg/dl* 1.70 (0.10–3.00) 4.90 (3.10–6.80) 9.5
Women Taking Hormone Replacement
Number of events 43 (4.5%) 36 (3.5%)
Person-yrs of follow-up 9,451 10,159
HR (95% CI)
Age adjusted 1 0.76 (0.49–1.18) 0
Framingham adjusted‡ 1 0.83 (0.53–1.29) 0
Fully adjusted§ 1 0.79 (0.50–1.25) 0
Women Taking Hormone Replacement
Number of events 43 (2.8%) 42 (3.1%)
Person-yrs of follow-up 15,142 13,460
HR (95% CI)
Age adjusted 1 1.16 (0.76–1.78) 0
Framingham adjusted‡ 1 1.26 (0.82–1.93) 0
Fully adjusted§ 1 1.36 (0.89–2.09) 0
Lipoprotein(a) quintile levels were derived from women taking hormone replacement therapy. †M
ge, blood pressure categories, current smoking status, total cholesterol, and high-density lipopro
urrent smoking status, total cholesterol, and high-density lipoprotein values as well as body mas
Abbreviations as in Tables 1 and 2.ssay (5,6) that has complicated many prior studies of Lp(a),
he large number of women studied, and the number of
ardiovascular end points. Although we consider indepen-
ence of the assay from apo(a) isoforms a particular
trength, it is possible that additional information can be
ained by measuring apo(a) isoforms reproducibly. The size
f this cohort of women helps us to evaluate what a number
f prior epidemiological studies (26–31,45) and randomized
ontrolled trials (46,47), although reporting the association
f HT with lower Lp(a) levels, were not powered to assess
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scular Events
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Lp(a), Hormone Therapy, and Risk of CVD July 8, 2008:124–31n relationship to actual hard cardiovascular outcomes. Our
ata address this question in a primary prevention cohort of
omen, and confirm trends reported previously in second-
ry prevention cohorts (32).
Limitations include the predominantly Caucasian nature
f our cohort, which does not allow us to assess potentially
ifferent relationships of plasma Lp(a) levels and CVD in
ifferent ethnic groups (48–50). Also, HT use in women is
ontroversial, and since the publication of the Women’s
ealth Initiative (20) and HERS I (Heart and Estrogen/
rogestin Replacement Study I) (21) and HERS II (22)
tudies, the American Heart Association (23), the U.S.
ood and Drug Administration (24), and the U.S. Preven-
ive Services Task Force (25) recommend against the use of
strogen and progestin or progesterone for prevention of
hronic conditions or for the primary or secondary preven-
ion of CVD (51). However, treatment of menopausal
ymptoms, although controversial, remains an indication for
ersonalized estrogen use, and new practice standards are
merging to help tailor HRT for menopausal symptoms for
hort-term use (24,52).
onclusions
n summary, these data suggest that the predictive utility of
p(a) is attenuated among women taking HT. The data
ay inform clinicians’ interpretations of Lp(a) values in
heir patients who are concurrently taking HT.
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